D Vijaya Nagini, MSR Krishna, S Karthikeyan
D Vijaya Nagini, MSR Krishna*, S Karthikeyan
Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur District, India.
Volume - 13,
Issue - 11,
Year - 2020
Diabetes mellitus (DM), a metabolic syndrome is marked by high measures of blood glucose due to lack of insufficient secretion of insulin. In the present study, photochemical compounds from Ferula asafoetida plant seeds were extracted and were analyzed about its inhibitory effects against Dipeptidyl peptidase (DPP)-IV using autodock studies. The GC-MS analysis confirmed that 12 active compounds were present in seed extract. Molecular docking studies showed four compounds viz., Ethoxydi (tert-butyl) silane, 9,12-octadecadienoic acid, Methyl- Tetra- decanoate and Hexadecanoic showed better inhibitory effect compared with standard DPP-IV inhibitor saxagliptin. In future these identified compounds can be used as a potential lead molecule for diabetic treatment compared to the standard drugs.
Cite this article:
D Vijaya Nagini, MSR Krishna, S Karthikeyan. Identification of Novel Dipeptidyl Peptidase -IV Inhibitors from Ferula asafoetida through GC-MS and Molecular Docking Studies. Research J. Pharm. and Tech. 2020; 13(11):5072-5076. doi: 10.5958/0974-360X.2020.00888.4
1. Pandeya, S. N., Kumar, R., Kumar, A., and Pathak, A. K. (2010). Antidiabetics Review on Natural Products. Research Journal of Pharmacy and Technology, 3(2), 300-318.
2. Awasthi A, Parween N, Singh VK, Anwar A, Prasad B, Kumar J. 2016. Diabetes: Symptoms, Cause and Potential Natural Therapeutic Methods. Adv. in Diabetes and Metabolism.4: 10-23.
3. Turdu G, Gao H, Jiang Y, Kabas M. 2018. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review. Future Medicinal Chemistry. 10(10):1229-1239.
4. Kumari, M. S., Babu, M. K., Sulthana, R., Srinivas, M., and Prasanthi, C. 2014. Diabetes Mellitus: Present status and Drug therapy Updates. Research Journal of Pharmacy and Technology, 7(1), 84-94.
5. Drucker DJ, Nauck MA. 2006. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705.
6. Kamtekar, S., and Keer, V. 2014. Management of Diabetes: A Review. Research Journal of Pharmacy and Technology, 7(9), 1065-1072.
7. Verspohl EJ.2009. Novel Therapeutics for Type 2 Diabetes: Incretin Hormone Mimetics (glucagon-like peptide-1 receptor agonist) and dipeptidyl peptidase-4 inhibitors. Pharmacology Therapeutics. 124(1):113-38.
8. Singh AK. 2014. Dipeptidyl peptidase-4 inhibitors: novel mechanism of actions. Indian J Endocrinol Metab. 18(6): 753-9.
9. Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A, Trugnan G. 1992. Dipeptidyl peptidase IV (CD26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2: cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J. Biol Chem. 267: 4824-4833.
10. Jiang C, Han S, Chen T, Chen J. 2012.3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors. Acta Pharmaceutica Sinica B. 2(4):411-420.
11. Zander M, Madsbad S, Madsen JL, Holst JJ. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 359:824-830.
12. Nisha J.2017. Molecular Docking Analysis of Potential Dipeptidyl peptidase- 4 (DPP-4) Inhibitors from Siddha formulation Pungampoo Chooranam for treating Diabetes mellitus. Int. J. Adv. Res. Biol. Sci. 4(10): 78-85.
13. Sheetz MJ, King GL. 2002. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 288 (20): 2579–2588.
14. Iranshahy M, Iranshahi M.2011.Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin)-A review. J. Ethnopharmacol. 134 (1): 1–10.
15. Abu-Zaiton, AS. 2010. Anti-diabetic activity of Ferula asafoetida extract in normal and alloxan-induced diabetic rats. Pak. J. Biol. Sci. 13: 97-100.
16. Dehpour AA, Ebrahimzadeh MA, Fazel NS, Mohammad NS.2009. Antioxidant activity of the methanol extract of Ferula asafoetida and its essential oil composition. Grasas Aceites. 60: 405-412.
17. Singh R. 2007. In vitro evaluation of aqueous and alcoholic extracts of spices for antifungal properties. Indian J. Anim. Sci. 77: 675-677.
18. Lee CL, Chiang LC, Cheng LH, Liaw CC, Abd El-Razek MH, Chang FR, Wu YC, 2009. Influenza A (H1N1) antiviral and cytotoxic agents from Ferula asafoetida. J. Nat. Prod. 72: 1568-1572.
19. Saleem M, Alam A, Sultana S. 2001. Asafoetida inhibits early events of carcinogenesis: a chemopreventive study. Life Sci. 68: 1913-1921.
20. Fatehi M, Farifteh F, Fatehi-Hassanabad Z. 2004. Antispasmodic and hypotensive effects of Ferula asafoetida gum extract. J. Ethnopharmacol. 91: 321-324.
21. Kumar P and Singh DK, 2006. Molluscicidal activity of Ferula asafoetida, Syzygium aromaticum and Carum carvi and their active components against the snail Lymnaea acuminata. Chemosphere, Lymnaea acuminata. Chemosphere. J. Agric. Food Chem.55: 9800-4.
22. Susmi, M. S., Kumar, R. S., Sreelakshmi, V., Menon, S. V., Mohan, S., Suja, S. T., and Manakadan, A. A. 2015. A Computational approach for identification of Phytochemicals for targeting and optimizing the inhibitors of Heat shock proteins. Research Journal of Pharmacy and Technology, 8(9), 1199-1204.
23. Wajida NS, Tanim MAH, Siddique TI, Hoque A, Sultana S, Meem M, Paul R, Abu Hena MS, Majumder M, Paul A.2018.In silico docking studies of some isolated compounds of Clausena lansium (Lou.) against diabetic activity. J Pharmacol Clin Toxicol. Vol. 6, Issue 1, pp: 1-3.
24. Cichero E, Espinoza S, Franchini S, Guariento S, Brasili L, Gainetdinov RR, Fossa P. 2014. Further insights into the pharmacology of the human trace amine-associated receptors: Discovery of novel ligands for TAAR1 by a virtual screening approach. Chem. Biol. Drug Des. 84:712–720.
25. Mukherjee PK.2002. An Approach to Evaluation of Botanicals: Quality Control of Herbal Drugs. 1st ed. New Delhi: Business Horizon Publication. p:405-6.
26. Lamarck JB, Pierre Antoine M. 1914.Zoological Philosophy. Macmillan. London pp: 125-135.
27. Ghosh AK, Palit S, Samajdar S. 2017.Insilco molecular docking study of Dihydroisoquinolinium derivatives as DPP IV inhibitors in type II Diabetes Mellitus. Pharma Tutor. 5(6);22-28
28. Ahmed HA, Alkali IY, Mahmud AF. 2018. In silico Molecular Docking Studies of Some Phytochemicals against Dipeptidyl peptidase 4. International Research Journal of Pharmacy and Medical Sciences (IRJPMS). Volume 1, Issue 6:65-68.